Beijing Lüzhu Biotechnology Co., Ltd. announced that it has received $54.1 million in funding from CCB International Asset Management Ltd., Zhuhai Livzon Pharmaceutical Equity Investment Management Co., Ltd., Hangzhou Tigermed Consulting Co., Ltd
Beijing Lüzhu Biotechnology Co., Ltd. announced that it has received $54,100,000 in a round of funding led by CCB International Asset Management Ltd. on August 31, 2021. The transaction also included participation from Zhuhai Livzon Pharmaceutical Equity Investment Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.